Delivery of Melittin as a Lytic Agent via Graphene Nanoparticles as Carriers to Breast Cancer Cells
Source abstract
Abstract
Melittin, as an agent to lyse biological membranes, may be a promising therapeutic agent in the treatment of cancer. However, because of its nonspecific actions, there is a need to use a delivery method. The conducted research determined whether carbon nanoparticles, such as graphene and graphene oxide, could be carriers for melittin to breast cancer cells. The studies included the analysis of intracellular pH, the potential of cell membranes, the type of cellular transport, and the expression of receptor proteins. By measuring the particle size, zeta potential, and FT-IT analysis, we found that the investigated nanoparticles are connected by electrostatic interactions. The level of melittin encapsulation with graphene was 86%, while with graphene oxide it was 78%. A decrease in pHi was observed for all cell lines after administration of melittin and its complex with graphene. The decrease in membrane polarization was demonstrated for all lines treated with melittin and its complex with graphene and after exposure to the complex of melittin with graphene oxide for the MDA-MB-231 and HFFF2 lines. The results showed that the investigated melittin complexes and the melittin itself act differently on different cell lines (MDA-MB-231 and MCF-7). It has been shown that in MDA-MD-231 cells, melittin in a complex with graphene is transported to cells via caveolin-dependent endocytosis. On the other hand, the melittin–graphene oxide complex can reach breast cancer cells through various types of transport. Other differences in protein expression changes were also observed for tumor lines after exposure to melittin and complexes.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Healthcare and Venom Research · Bee Products Chemical Analysis · Venomous Animal Envenomation and Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, 02-786 Warsaw, Poland
Faculty of Chemical and Process Engineering, Warsaw University of Technology, 00-654 Warsaw, Poland
References (100+)
Show source-provided references
1. Role of MicroRNA/LncRNA Intertwined With the Wnt/β-Catenin Axis in Regulating the Pathogenesis of Triple-Negative Breast Cancer10.3389/fphar.2022.814971 ↗
2. (2022, October 25). Breast Cancer: Statistics | Cancer.Net. Available online: https://www.cancer.net/cancer-types/breast-cancer/statistics.
3. Rivera-Yañez, N., Rivera-Yañez, C.R., Pozo-Molina, G., Méndez-Catalá, C.F., Méndez-Cruz, A.R., and Nieto-Yañez, O. (2021). Biomedical Properties of Propolis on Diverse Chronic Diseases and Its Potential Applications and Health Benefits. Nutrients, 13.10.3390/nu13010078 ↗
4. Venom Peptides in Cancer Therapy: An Updated Review on Cellular and Molecular Aspects10.1016/j.phrs.2020.105327 ↗
5. Beneficial Role of Insect-Derived Bioactive Components against Inflammation and Its Associated Complications (Colitis and Arthritis) and Cancer10.1016/j.cbi.2019.108824 ↗
6. A Critical Review and Perspective of Honey in Tissue Engineering and Clinical Wound Healing10.1089/wound.2018.0848 ↗
7. Yupanqui Mieles, J., Vyas, C., Aslan, E., Humphreys, G., Diver, C., and Bartolo, P. (2022). Honey: An Advanced Antimicrobial and Wound Healing Biomaterial for Tissue Engineering Applications. Pharmaceutics, 14.10.3390/pharmaceutics14081663 ↗
8. Deglovic, J., Majtanova, N., and Majtan, J. (2022). Antibacterial and Antibiofilm Effect of Honey in the Prevention of Dental Caries: A Recent Perspective. Foods, 11.10.3390/foods11172670 ↗
9. Potential of Honey in the Treatment of Wounds and Burns10.2165/00128071-200102010-00003 ↗
10. Melittin: A Membrane-Active Peptide with Diverse Functions10.1007/s10540-006-9030-z ↗
11. How Do the Properties of Amphiphilic Polymer Membranes Influence the Functional Insertion of Peptide Pores?10.1021/acs.biomac.9b01416 ↗
12. Process of Inducing Pores in Membranes by Melittin10.1073/pnas.1307010110 ↗
13. How Does Melittin Permeabilize Membranes?10.1016/j.bpj.2017.11.3738 ↗
14. Impact of Bee Venom and Melittin on Apoptosis and Biotransformation in Colorectal Carcinoma Cell Lines
15. Melittin Inhibition and Eradication Activity for Resistant Polymicrobial Biofilm Isolated from a Dairy Industry after Disinfection10.1155/2019/4012394 ↗
16. Juśkiewicz, J., Rawicka, A., Fotschki, B., Majewski, M., and Zduńczyk, Z. (2021). Influence of Supplementation of Lactoferrin, Melittin and Cecropin A to Rat Diet on Changes in Faecal Ammonia Concentrations, Short-Chain Fatty Acid Concentrations and Activities of Bacterial Enzymes. Animals, 11.10.3390/ani11051203 ↗
17. Hong, J., Lu, X., Deng, Z., Xiao, S., Yuan, B., and Yang, K. (2019). How Melittin Inserts into Cell Membrane: Conformational Changes, Inter-Peptide Cooperation, and Disturbance on the Membrane. Molecules, 24.10.3390/molecules24091775 ↗
18. Insect Proteins as a Potential Source of Antimicrobial Peptides in Livestock Production. A Review10.22358/jafs/69998/2017 ↗
19. Time-Resolved SANS Reveals Pore-Forming Peptides Cause Rapid Lipid Reorganization10.1039/D0NJ04717A ↗
20. Melittin Induced Cytogenetic Damage, Oxidative Stress and Changes in Gene Expression in Human Peripheral Blood Lymphocytes10.1016/j.toxicon.2015.12.005 ↗
21. Carpena, M., Nuñez-Estevez, B., Soria-Lopez, A., and Simal-Gandara, J. (2020). Bee Venom: An Updating Review of Its Bioactive Molecules and Its Health Applications. Nutrients, 12.10.3390/nu12113360 ↗
22. Bee Venom Therapy: Potential Mechanisms and Therapeutic Applications10.1016/j.toxicon.2018.04.012 ↗
23. Bee Venom and Hesperidin Effectively Mitigate Complete Freund’s Adjuvant-Induced Arthritis Via Immunomodulation and Enhancement of Antioxidant Defense System10.5606/ArchRheumatol.2018.6519 ↗
24. Anti-Cancer Effect of Bee Venom in Prostate Cancer Cells through Activation of Caspase Pathway via Inactivation of NF-ΚB10.1002/pros.21296 ↗
25. Ceremuga, M., Stela, M., Janik, E., Gorniak, L., Synowiec, E., Sliwinski, T., Sitarek, P., Saluk-Bijak, J., and Bijak, M. (2020). Melittin-A Natural Peptide from Bee Venom Which Induces Apoptosis in Human Leukaemia Cells. Biomolecules, 10.10.3390/biom10020247 ↗
26. First Report on the Isolation of Melittin from Iranian Honey Bee Venom and Evaluation of Its Toxicity on Gastric Cancer AGS Cells10.1016/j.jcma.2015.06.008 ↗
27. Effects of Melittin on Growth and Angiogenesis of Human Hepatocellular Carcinoma BEL-7402 Cell Xenografts in Nude Mice
28. The Anti-Cancer Potency and Mechanism of a Novel Tumor-Activated Fused Toxin, DLM10.3390/toxins7020423 ↗
29. Daniluk, K., Kutwin, M., Grodzik, M., Wierzbicki, M., Strojny, B., Szczepaniak, J., Balaban, J., Sosnowska, M., Chwalibog, A., and Sawosz, E. (2020). Use of Selected Carbon Nanoparticles as Melittin Carriers for MCF-7 and MDA-MB-231 Human Breast Cancer Cells. Materials, 13.10.3390/ma13010090 ↗
30. Melittin Inhibits Proliferation, Migration and Invasion of Bladder Cancer Cells by Regulating Key Genes Based on Bioinformatics and Experimental Assays10.1111/jcmm.14775 ↗
31. Melittin Inhibits Tumor Angiogenesis Modulated by Endothelial Progenitor Cells Associated with the SDF-1α/CXCR4 Signaling Pathway in a UMR-106 Osteosarcoma Xenograft Mouse Model10.3892/mmr.2016.5215 ↗
32. Three Valuable Peptides from Bee and Wasp Venoms for Therapeutic and Biotechnological Use: Melittin, Apamin and Mastoparan10.3390/toxins7041126 ↗
33. Studies on Anticancer Activities of Antimicrobial Peptides10.1016/j.bbamem.2007.11.008 ↗
34. Melittin: A Lytic Peptide with Anticancer Properties10.1016/j.etap.2013.06.009 ↗
35. Dendrimers as Nanoscale Vectors: Unlocking the Bars of Cancer Therapy10.1016/j.semcancer.2022.06.003 ↗
36. Cellular and Subcellular Interactions of Graphene-Based Materials with Cancerous and Non-Cancerous Cells10.1016/j.addr.2022.114467 ↗
37. The Inhibition of Migration and Invasion of Cancer Cells by Graphene via the Impairment of Mitochondrial Respiration10.1016/j.biomaterials.2013.11.020 ↗
38. Vacuolization in Cytoplasm and Cell Membrane Permeability Enhancement Triggered by Micrometer-Sized Graphene Oxide10.1021/acsnano.5b01685 ↗
39. Toxicity of Graphene-Family Nanoparticles: A General Review of the Origins and Mechanisms10.1186/s12989-016-0168-y ↗
40. Differential Cytotoxicity and Internalization of Graphene Family Nanomaterials in Myocardial Cells10.1016/j.msec.2016.12.080 ↗
41. Plasma Membrane Changes during Programmed Cell Deaths10.1038/cr.2017.133 ↗
42. Caspase-Mediated Loss of Mitochondrial Function and Generation of Reactive Oxygen Species during Apoptosis10.1083/jcb.200208089 ↗
43. Modulation of Tryptophan Environment in Membrane-Bound Melittin by Negatively Charged Phospholipids: Implications in Membrane Organization and Function10.1021/bi971933j ↗
44. CD105 (Endoglin) Exerts Prognostic Effects via Its Role in the Microvascular Niche of Paediatric High Grade Glioma10.1007/s00401-012-0952-1 ↗
45. Aburayan, W.S., Alajmi, A.M., Alfahad, A.J., Alsharif, W.K., Alshehri, A.A., Booq, R.Y., Alsudir, S.A., Alsulaihem, F.M., Bukhary, H.A., and Badr, M.Y. (2022). Melittin from Bee Venom Encapsulating Electrospun Fibers as a Potential Antimicrobial Wound Dressing Patches for Skin Infections. Pharmaceutics, 14.10.3390/pharmaceutics14040725 ↗
46. Chemical and Structural Properties of Reduced Graphene Oxide—Dependence on the Reducing Agent10.1007/s10853-020-05461-1 ↗
47. Breast Cancer Treatment
48. Chrysin Suppresses HT-29 Cell Death Induced by Diclofenac through Apoptosis and Oxidative Damage10.1080/01635581.2020.1801775 ↗
49. Honeybee Venom and Melittin Suppress Growth Factor Receptor Activation in HER2-Enriched and Triple-Negative Breast Cancer10.1038/s41698-020-00129-0 ↗
50. Kinetics and Mechanism of Hemolysis Induced by Melittin and by a Synthetic Melittin Analogue10.1016/S0006-3495(82)84681-X ↗
51. Soliman, C., Eastwood, S., Truong, V.K., Ramsland, P.A., and Elbourne, A. (2019). The Membrane Effects of Melittin on Gastric and Colorectal Cancer. PLoS ONE, 14.10.1371/journal.pone.0224028 ↗
52. Anti-Breast Cancer Activity on MCF-7 Cells of Melittin from Indonesia’s Apis Cerana: An In Vitro Study10.31557/APJCP.2021.22.12.3913 ↗
53. Melittin-MIL-2 Fusion Protein as a Candidate for Cancer Immunotherapy10.1186/s12967-016-0910-0 ↗
54. A Novel Melittin Nano-Liposome Exerted Excellent Anti-Hepatocellular Carcinoma Efficacy with Better Biological Safety10.1186/s13045-017-0442-y ↗
55. Synergistic Co-Delivery of Doxorubicin and Melittin Using Functionalized Magnetic Nanoparticles for Cancer Treatment: Loading and in Vitro Release Study by LC–MS/MS10.1080/21691401.2018.1536063 ↗
56. Co-Delivery of Paclitaxel and Melittin by Glycopeptide-Modified Lipodisks for Synergistic Anti-Glioma Therapy10.1039/C9NR01820D ↗
57. Construction of a Supramolecular Förster Resonance Energy Transfer System and Its Application Based on the Interaction between Cy3-Labeled Melittin and Phosphocholine Encapsulated Quantum Dots10.1021/am3000984 ↗
58. Delivery of Melittin-Loaded Niosomes for Breast Cancer Treatment: An in Vitro and in Vivo Evaluation of Anti-Cancer Effect10.1186/s12645-021-00085-9 ↗
59. Targeting Lipodisks Enable Selective Delivery of Anticancer Peptides to Tumor Cells10.1016/j.nano.2017.06.020 ↗
60. Prolonged Analgesic Effect of PLGA-Encapsulated Bee Venom on Formalin-Induced Pain in Rats10.1016/j.ijpharm.2009.06.034 ↗
61. Graphene Oxide-Based Magnetic Nanocomposites for the Delivery of Melittin to Cervical Cancer HeLa Cells10.1088/1361-6528/ab5084 ↗
62. Effect of Zeta Potential on the Properties of Nano-Drug Delivery Systems—A Review (Part 2)
63. Increased H+ Efflux Is Sufficient to Induce Dysplasia and Necessary for Viability with Oncogene Expression10.7554/eLife.03270 ↗
64. Upregulation of NHE1 Protein Expression Enables Glioblastoma Cells to Escape TMZ-Mediated Toxicity via Increased H+ Extrusion, Cell Migration and Survival10.1093/carcin/bgu089 ↗
65. Regulation of Intracellular PH10.1152/advan.00045.2004 ↗
66. The Na+/H+ Exchanger NHE1, but Not the Na+, HCO3(-) Cotransporter NBCn1, Regulates Motility of MCF7 Breast Cancer Cells Expressing Constitutively Active ErbB210.1016/j.canlet.2011.11.023 ↗
67. Triple-Edged Therapy Targeting Intracellular Alkalosis and Extracellular Acidosis in Cancer10.1016/j.semcancer.2017.01.006 ↗
68. Deficits in Elevating Membrane Potential of Rat Fibrosarcoma Cells after Cell Contact
69. Electrical Potential Measurements in Human Breast Cancer and Benign Lesions10.1159/000217885 ↗
70. Quicke, P., Sun, Y., Arias-Garcia, M., Acker, C.D., Djamgoz, M.B.A., Bakal, C., and Foust, A.J. (2021). Membrane Voltage Fluctuations in Human Breast Cancer Cells. bioRxiv.10.1101/2021.12.20.473148 ↗
71. Dutta, D., Williamson, C.D., Cole, N.B., and Donaldson, J.G. (2012). Pitstop 2 Is a Potent Inhibitor of Clathrin-Independent Endocytosis. PLoS ONE, 7.10.1371/journal.pone.0045799 ↗
72. Zhang, W., Zhou, Q.M., and Du, G.H. (2022). Colchicine. Natural Small Molecule Drugs from Plants, Sringer.
73. Colchicine—Update on Mechanisms of Action and Therapeutic Uses10.1016/j.semarthrit.2015.06.013 ↗
74. Cytochalasin D Acts as an Inhibitor of the Actin–Cofilin Interaction10.1016/j.bbrc.2012.06.063 ↗
75. Effect of Genistein, a Tyrosine-Specific Protein Kinase Inhibitor, on Cell Rounding by PH Upshifting10.1007/BF02633988 ↗
76. Effect of Phenylarsine Oxide on Fluid Phase Endocytosis: Further Evidence for Activation of the Glucose Transporter10.1002/jcp.1041410304 ↗
77. Fc Receptor-Mediated Phagocytosis Requires CDC42 and Rac110.1093/emboj/17.21.6219 ↗
78. Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway10.1124/pr.54.4.561 ↗
79. Dynasore—Not Just a Dynamin Inhibitor10.1186/s12964-015-0102-1 ↗
80. Molecular Structure, Function, and Dynamics of Clathrin-Mediated Membrane Traffic10.1101/cshperspect.a016725 ↗
81. Expression of the Cell to Cell Adhesion Molecule, ALCAM, in Breast Cancer Patients and the Potential Link with Skeletal Metastasis
82. Loss of ALCAM Expression Is Linked to Adverse Phenotype and Poor Prognosis in Breast Cancer: A TMA-Based Immunohistochemical Study on 2,197 Breast Cancer Patients10.3892/or.2014.3523 ↗
83. Clinical Implications of Activated Leukocyte Cell Adhesion Molecule Expression in Breast Cancer10.1007/s11033-011-0783-5 ↗
84. ALCAM/CD166 Protects Breast Cancer Cells against Apoptosis and Autophagy
85. The Hydrophobic Pocket of 24p3 Protein from Mouse Uterine Luminal Fluid: Fatty Acid and Retinol Binding Activity and Predicted Structural Similarity to Lipocalins10.1111/j.1399-3011.1998.tb00663.x ↗
86. The Lipocalin Protein Family: A Role in Cell Regulation10.1016/0014-5793(94)01078-1 ↗
87. Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy10.3389/fphys.2016.00430 ↗
88. Lipocalin 2: A Potential Therapeutic Target for Breast Cancer Metastasis10.2147/OTT.S181223 ↗
89. Relationships of Lipocalin 2 with Breast Tumorigenesis and Metastasis10.1002/jcp.22403 ↗
90. Neutrophil Gelatinase-Associated Lipocalin as a Survival Factor10.1042/BJ20051020 ↗
91. Gene-Expression Profiling Predicts Recurrence in Dukes’ C Colorectal Cancer10.1053/j.gastro.2005.06.066 ↗
92. The Neutrophil Gelatinase-Associated Lipocalin (NGAL), a NF-KappaB-Regulated Gene, Is a Survival Factor for Thyroid Neoplastic Cells10.1073/pnas.0710846105 ↗
93. Lipocalin2 Expressions Correlate Significantly With Tumor Differentiation in Epithelial Ovarian Cancer10.1369/jhc.2009.953257 ↗
94. Protective Effects of Lipocalin-2 (LCN2) in Acute Liver Injury Suggest a Novel Function in Liver Homeostasis10.1016/j.bbadis.2013.01.014 ↗
95. Induction of Lipocalin-2 Expression in Acute and Chronic Experimental Liver Injury Moderated by pro-Inflammatory Cytokines Interleukin-1β through Nuclear Factor-ΚB Activation10.1111/j.1478-3231.2011.02495.x ↗
96. Urokinase-Type Plasminogen Activator Receptor (UPAR) Expression Enhances Invasion and Metastasis in RAS Mutated Tumors
97. Multifaceted Role of the Urokinase-Type Plasminogen Activator (UPA) and Its Receptor (UPAR): Diagnostic, Prognostic, and Therapeutic Applications10.3389/fonc.2018.00024 ↗
98. Prognostic Significance of UPA and UPAR Expression in Patients with Cervical Cancer Undergoing Radiotherapy10.3892/ol.2021.12684 ↗
99. First-in-Human UPAR PET: Imaging of Cancer Aggressiveness10.7150/thno.12956 ↗
100. The Urokinase Plasminogen Activator System: A Rich Source of Tumour Markers for the Individualised Management of Patients with Cancer10.1016/j.clinbiochem.2004.05.013 ↗